Erythropoietin Augments Survival of Glioma Cells After Radiation and Temozolomide

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 3, 2008, Pages 927-934

  Hassouna, Imam ^a   Sperling, Swetlana ^a   Kim, Ella ^b   Schulz Schaeffer, Walter ^b   Rave Fränk, Margret ^b   Hasselblatt, Martin ^c   Jelkmann, Wolfgang ^d   Giese, Alf ^b   Ehrenreich, Hannelore ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Clonogenic survival; Migration; Proliferation; Recombinant human EPO; Xenograft model

Indexed keywords

ANIMAL CELL CULTURE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELLS; ECOLOGY; GROWTH KINETICS; IRRADIATION; TUMORS;

BENEFICIAL EFFECTS; CELL LINES; CELL MIGRATION; CHEMORADIATION; CLONOGENIC SURVIVAL; COLLATERAL DAMAGE; DOSE-DEPENDENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROPOIETIN (EPO); GLIOBLASTOMA; GLIOMA CELLS; GLIOSARCOMA; IN-CELL; IN-VIVO; INTRAPERITONEAL; MIGRATION; NEURAL TISSUES; NEUROPROTECTION; NUDE MICE; PRE-INCUBATION; PROLIFERATION; QUALITY OF LIFE; RECOMBINANT HUMAN EPO; REVERSE TRANSCRIPTASE- POLYMERASE CHAIN REACTION; TEMOZOLOMIDE; TUMOR GROWTH; XENOGRAFT MODEL;

CYTOLOGY;

EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COMBINED MODALITY THERAPY; DACARBAZINE; ERYTHROPOIETIN; GLIOMA; GLIOSARCOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 52949105368     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.06.1923     Document Type: Article

References (45)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Butler J.M., Rapp S.R., and Shaw E.G. Managing the cognitive effects of brain tumor radiation therapy. Curr Treat Options Oncol 7 (2006) 517-523
3. Byrne T.N. Cognitive sequelae of brain tumor treatment. Curr Opin Neurol 18 (2005) 662-666
4. Jelkmann W. Erythropoietin after a century of research: Younger than ever. Eur J Haematol 78 (2007) 183-205
5. Sakanaka M., Wen T.C., Matsuda S., et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95 (1998) 4635-4640
6. Bernaudin M., Marti H.H., Roussel S., et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19 (1999) 643-651
7. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97 (2000) 10526-10531
8. Siren A.L., Radyushkin K., Boretius S., et al. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain 129 (2006) 480-489
9. Ehrenreich H., Fischer B., Norra C., et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130 (2007) 2577-2588
10. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
11. Ehrenreich H., Hinze-Selch D., Stawicki S., et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12 (2007) 206-220
12. Campana W.M., and Myers R.R. Erythropoietin and erythropoietin receptors in the peripheral nervous system: Changes after nerve injury. FASEB J 15 (2001) 1804-1806
13. Celik M., Gokmen N., Erbayraktar S., et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99 (2002) 2258-2263
14. Kertesz N., Wu J., Chen T.H., et al. The role of erythropoietin in regulating angiogenesis. Dev Biol 276 (2004) 101-110
15. Keswani S.C., Buldanlioglu U., Fischer A., et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 56 (2004) 815-826
16. Konishi Y., Chui D.H., Hirose H., et al. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609 (1993) 29-35
17. Shingo T., Sorokan S.T., Shimazaki T., et al. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21 (2001) 9733-9743
18. Siren A.L., Fratelli M., Brines M., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98 (2001) 4044-4049
19. Erbayraktar S., de Lanerolle N., de Lotbiniere A., et al. Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med 12 (2006) 74-80
20. Bianchi R., Gilardini A., Rodriguez-Menendez V., et al. Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 43 (2007) 710-717
21. Pinel S., Barberi-Heyob M., Cohen-Jonathan E., et al. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 59 (2004) 250-259
22. Stuben G., Thews O., Pottgen C., et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 127 (2001) 346-350
23. Acs G., Zhang P.J., McGrath C.M., et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162 (2003) 1789-1806
24. Belenkov A.I., Shenouda G., Rizhevskaya E., et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3 (2004) 1525-1532
25. Kumar S.M., Acs G., Fang D., et al. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166 (2005) 823-830
26. Liu W.M., Powles T., Shamash J., et al. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 23 (2004) 981-990
27. Mohyeldin A., Dalgard C.L., Lu H., et al. Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg 106 (2007) 338-350
28. Osterborg A., Aapro M., Cornes P., et al. Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43 (2007) 510-519
29. Yin D., Kawabata H., Tcherniamtchouk O., et al. Glioblastoma multiforme cells: Expression of erythropoietin receptor and response to erythropoietin. Int J Oncol 31 (2007) 1193-1198
30. Baz R., Walker E., Choueiri T.K., et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 117 (2007) 162-167
31. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50 (2001) 705-715
32. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
33. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
34. Kim E.L., Yoshizato K., Kluwe L., et al. Comparative assessment of the functional p53 status in glioma cells. Anticancer Res 25 (2005) 213-224
35. Kaczarek E., Zapf S., Bouterfa H., et al. Dissecting glioma invasion: Interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. Int J Dev Neurosci 17 (1999) 625-641
36. Bromley R., Davey R., Oliver L., et al. A preliminary investigation of cell growth after irradiation using a modulated x-ray intensity pattern. Phys Med Biol 51 (2006) 3639-3651
37. Giese A., Rief M.D., Loo M.A., et al. Determinants of human astrocytoma migration. Cancer Res 54 (1994) 3897-3904
38. Akudugu J.M., Binder A., Serafin A., et al. Changes in G1-phase populations in human glioblastoma and neuroblastoma cell lines influence p66/Be neutron-induced micronucleus yield. Life Sci 75 (2004) 623-632
39. Lamszus K., Brockmann M.A., Eckerich C., et al. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11 (2005) 4934-4940
40. Kantelhardt S.R., Leppert J., Krajewski J., et al. Imaging of brain and brain tumor specimens by time-resolved multiphoton excitation microscopy ex vivo. Neuro Oncol 9 (2007) 103-112
41. Banks W.A., Jumbe N.L., Farrell C.L., et al. Passage of erythropoietic agents across the blood-brain barrier: A comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 505 (2004) 93-101
42. Shinojima N., Tada K., Shiraishi S., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63 (2003) 6962-6970
43. Lövey J., Bereczky B., Gilly R., et al. Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels. Strahlenther Onkol 184 (2008) 1-7
44. Sartelet H., Fabre M., Castaing M., et al. Expression of erythropoietin and its receptor in neuroblastomas. Cancer 110 (2007) 1096-1106
45. Mittelbronn M., Capper D., Bunz B., et al. De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol 33 (2007) 299-307